



5 May 2021

Opyl appoints Dr Megan Robertson to its Board

Melbourne, Australia – Opyl Limited (ASX:OPL) today announces the appointment of Dr Megan Robertson to the Opyl Board as a non-executive director effective from today bringing extensive clinical trial expertise and experiences to the company.

Opyl Chairman, Dr Julian Chick, said: "We are extremely pleased to welcome Megan to the Board. Megan brings an enormous amount of clinical and commercial experience and in-depth knowledge in the health sector which will contribute significantly to the company's strategy. Megan's expertise and networks will complement the Opyl leadership team, particularly as we further commercialise our product offerings."

Megan is an alumna of the University of Melbourne where she completed a Bachelor of Medicine, Bachelor of Surgery (MBBS). She is the current Group Chief Research Officer at St Vincent's Health Australia and Director of Research at St Vincent's Hospital, Melbourne. She also works as a Senior Intensive Care Consultant at Epworth HealthCare (Richmond and Freemasons). She is on the boards of the Digital Health CRC, St Vincent's Institute of Medical Research, FearLess (PTSD-ANZ), and Queen's College (Univ of Melbourne), and the Tuckwell Scholarship Selection Panel at ANU. She also works with national bodies including the Australian Commission on Safety and Quality in Healthcare, AusBiotech, and the National Health and Medical Research Council. Previously, she held positions as the Director of Professional Affairs, CICM, as the Executive Director of Research at Epworth HealthCare, and as the Co-Director of the Intensive Care Unit at Epworth Freemasons.

She has successfully led major initiatives in the St Vincent's Research Directorate including the establishment of the St Vincent's Research Valet Service, development of the Victorian Clinical Trial Gateway portal, Clinical Trials Business Development model, facilitated research activities of the Research Governance Unit, and built linkages between clinicians/researchers and industry, as well as linkages between clinicians/researchers and community.

Megan is a fellow of the Royal Australian College of Physicians (FRACP), the Australian and New Zealand College of Anaesthetists (FANZCA) and the College of Intensive Care Medicine (FCICM).

In accepting the board position Megan said: "Opyl has set a tremendous foundation for its technology platforms and with my clinical expertise and experience, I see the capability and global opportunity for the company. It is with great excitement and enthusiasm that I join the Opyl board to assist in making a significant contribution to the ongoing growth of the business."

The Board has authorised this announcement for release to the ASX.

-ENDS-

For media enquiries: Laura Blue +61 416 699 925
For investor enquiries: info@opyl.ai
www.opyl.ai



Opyl is a new generation Australian company that provides leading biopharma and health organisations access to emerging AI-assisted technologies and real-world data insights to understand and improve healthcare design, development, and delivery.

Opyl works at the intersection of clinical trials, artificial intelligence, and social media.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment and retention solutions
- clinical trial predictive analytics
- deep social media insights

Our vision is to improve health and wellness by optimising data assets and digital activation to advance technologies for life.

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook